Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 6, 2015, Pages 588-595

  Park, Sang Ho ^a   Rha, Seung Woon ^b   Choi, Byoung Geol ^b   Park, Ji Young ^c   Jeon, Ung ^a   Seo, Hong Seog ^b   Kim, Eung Ju ^b   Na, Jin Oh ^b   Choi, Cheol Ung ^b   Kim, Jin Won ^b   Lim, Hong Euy ^b   Park, Chang Gyu ^b   Oh, Dong Joo ^b  

^a Soonchunhyang University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Eulji University School of Medicine   (South Korea)

Author keywords

Angina; Coronary; Lipoprotein(a); Restenosis; Stents

Indexed keywords

LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ANGINA PECTORIS; ANGIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG ELUTING STENT; FEMALE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; STENT THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; ETHNOLOGY; HEALTH SURVEY; MIDDLE AGED; PROSPECTIVE STUDY; RADIOGRAPHY; REGISTER; RESTENOSIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84930337711     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12396     Document Type: Article

References (29)

1. Utermann G. The mysteries of lipoprotein (a). Science 1989; 246: 904-10.
2. Akita H, Matsubara M, Shibuya H, Fuda H, Chiba H. Effect of ageing on plasma lipoprotein(a) levels. Ann. Clin. Biochem. 2002; 39: 237-40.
3. Craig WY, Ledue TB. Lipoprotein(a) and the acute phase response. Clin. Chim. Acta. 1992; 210: 231-2.
4. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein (a) as an acute phase protein. Atherosclerosis 1989; 78: 145-50.
5. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risk associated with lipoprotein (a). Nature 1989; 339: 301-3.
6. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 1993; 260: 1655-8.
7. Desmarais RL, Sarembock IJ, Ayers CR, Velmon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91: 1403-9.
8. Zairis MN, Ambrose JA, Manousakis SJ et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J. Am. Coll. Cardiol. 2002; 40: 1375-82.
9. Kamitani T, Taniguchi T, Miyai N, Kawasaki T, Kawasaki S, Sugihara H. Association between plasma lipoprotein(a) concentration and restenosis after stent implantation. Circ. J. 2005; 69: 644-9.
10. Nicholls SJ, Tang WH, Scoffone H et al. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J. Lipid Res. 2010; 51: 3055-61.
11. Ribichini F, Steffenino G, Dellavalle A et al. Plasma lipoprotein(a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998; 98: 1172-7.
12. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur. Heart J. 2010; 31: 2844-53.
13. Nielsen LB, Gronholdt MLM, Schroeder TV, Stender S, Nordestgaard BG. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 905-11.
14. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: Mechanistic insights from animal models. Clin. Biochem. 2004; 37: 333-43.
15. Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997; 96: 2514-19.
16. Kardys I, Oemrawsingh RM, Kay IP et al. Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention. Clin. Cardiol. 2012; 35: 482-9.
17. Qin SY, Liu J, Jiang HX, Hu BL, Zhou Y, Olkkonen VM. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: Meta-analysis of 9 cohort studies. Atherosclerosis 2013; 227: 360-6.
18. Feric NT, Boffa MB, Johnston SM, Koschinsky ML. Apolipoprotein(a) inhibits theconversion of Glu-plasminogen to Lys-plasminogen: A novel mechanism forlipoprotein(a)-mediated inhibition of plasminogen activation. J. Thromb. Haemost. 2008; 6: 2113-20.
19. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease, 8th edn. McGraw-Hill, New York. 2001; 2753-87.
20. Matthews KA, Sowers MF, Derby CA et al. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). Am. Heart J. 2005; 149: 1066-73.
21. Jenner JL, Ordovas JM, Lamon-Fava S et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 1993; 87: 1135-41.
22. Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-23.
23. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 2008; 117: 176-84.
24. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313-19.
25. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: Recent advances and future directions. Clin. Chem. 2003; 49: 1785-96.
26. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995; 274: 1771-4.
27. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acidalone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210: 353-61.
28. Gouni-Berthold I, Berthold HK. Lipoprotein(a): Current perspectives. Curr. Vasc. Pharmacol. 2011; 9: 682-92.
29. Ellis SG, Vandormael MG, Cowley MJ et al. Coronary morphological and clinical determinations of procedural outcome with multivessel coronary artery disease: Implications for patient selection. Circulation 1990; 82: 1193-202.